350% rally in 3 years, multibagger pharma stock to be in focus on Wednesday | Key details from filing

350% rally in 3 years, multibagger pharma stock to be in focus on Wednesday | Key details from filing. Sudarshan Pharma Industries is under due diligence for acquiring a 9.50% stake in MedTherapy Biotechnology. This includes a 1.50% stake from its promoters. The acquisition aims to enhance its US market presence, with completion expected by March 2027. Shares of Sudarshan Pharma Industries are likely to attract investors' interest on Wednesday, September 16, after the company said the proposal to acquire a 9.50% equity stake in MedTherapy Biotechnology Inc., USA,